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ABSTRACT
We hypothesised that consumption of flavanol-containing apple puree would modulate platelet activity and increase nitric oxide metabolite status, and that high flavanol apple puree would exert a greater effect than low flavanol apple puree. 25 subjects consumed 230 g of apple puree containing 25 and 100 mg epicatechin (low and high flavanol apple puree, respectively) and aspirin (75 mg) in random order. Measurements were made at baseline, acutely after treatment (2, 6 and 24 h), and after 14 d of treatment. Low flavanol apple puree significantly attenuated ADP and epinephrine-induced integrin-β3 expression 2 h and 6 h after consumption and ADP and epinephrine-induced P-selectin expression within 2 h of consumption. High flavanol apple puree attenuated epinephrine and ADP-induced integrin-β3 expression after 2 and 6 h. ADP and epinephrine-induced integrin-β3 expression was significantly attenuated 2, 6 and 24 h after consumption of aspirin, while 14 d aspirin consumption attenuated collagen-induced P-selectin expression only.  The plasma total nitric oxide metabolite conc. was significantly increased 6 h after consumption of both low and high flavanol apple purees. In conclusion, consumption of apple purees containing ≥25 or 100 mg flavanols transiently attenuated ex vivo integrin-β3 and P-selectin expression and increased plasma nitric oxide metabolite conc. in healthy subjects, but the effect was not enhanced for the high flavanol apple puree.









Cardiovascular disease is one of the major causes of mortality worldwide; for example in both the US and the UK CVD accounts for around 35% of all deaths. The aetiology of CVD is multi-factorial but there is accumulating evidence from epidemiological investigations to suggest an association between improved cardiovascular health and a diet rich in flavanols  ADDIN EN.CITE (,). Flavanols are one of the 6 sub-classes of flavonoids and comprise monomeric flavanols or ‘catechins’ (catechin and epicatechin, and gallo and galloylated derivatives such as epigallocatechin gallate) and oligo-/polymeric flavanols collectively known as proanthocyanidins. Numerous short and long term intervention studies using healthy volunteers and at risk groups have reported on the effects of a variety of flavanol-rich plant foods and extracts on risk markers for CVD, and flavanols have been ascribed with various cardio-protective properties including anti-inflammatory () and anti-platelet activities  ADDIN EN.CITE (,), and the ability to reduce LDL oxidation () and improve endothelial function  ADDIN EN.CITE (). In a meta-analysis of randomized controlled trials designed to test the effects of flavonoids on established markers of CVD risk  ADDIN EN.CITE (), cocoa and chocolate were shown to significantly lower blood pressure and improve flow mediated dilation (FMD)​[1]​() of the brachial artery. FMD, a measure of endothelial function in humans, is almost exclusively mediated by nitric oxide (NO)  ADDIN EN.CITE (), a potent vasodilator. Cocoa consumption has been shown to cause acute increases in endothelial NO production  ADDIN EN.CITE () and there is evidence to show that this is likely mediated by epicatechin  ADDIN EN.CITE ().  
	Platelet activation and subsequent aggregation is a critical event occurring in the pathogenesis of CVD ().  Platelet aggregation is mediated by a surface fibrinogen receptor (integrin-β3). Once activated the integrin beta-3 binds fibrinogen and von Willibrand factor which are secreted in response to endothelial cell damage. The activated platelets in turn synthesize and secrete thromboxane A2 (TXA2) and intracellular ADP which, combined with conformational changes in the glycoprotein complex, result in platelet aggregation. Furthermore, P-selectin (an adhesion molecule situated in the membrane of the platelet α-granule) is mobilised to the platelet surface where it mediates platelet-leukocyte adhesion.  Anti-platelet therapies such as aspirin, which suppresses the production of TXA2, and integrin beta-3 inhibitors, are well recognized therapeutic regimes used in the prevention and treatment of cardiovascular disorders. Flavanol rich foods and beverages such as green tea, cocoa (and cocoa products) and grape juice have also been shown to modulate platelet function  ADDIN EN.CITE (,). Evidence for the anti-aggregatory effects of flavanol rich foods are arguably strongest for cocoa which has been shown to lower ADP and epinephrine activated platelet aggregation within 2-6 h of consumption  ADDIN EN.CITE (,), the effects of which were shown to be associated with a reduction in the expression of the surface protein integrin-β3. Flavanols mediate platelet function through a variety of mechanisms. Purple grape juice  ADDIN EN.CITE () and cocoa  ADDIN EN.CITE () for example have been shown to inhibit platelet protein kinase C and human platelet 12-lipoxygenase activity. Additionally, chocolate consumption has been shown to favourably affect eicosanoid synthesis providing evidence that flavanols may possess anti-inflammatory properties  ADDIN EN.CITE () . 
Flavanols are the major flavonoids consumed by humans, with their contribution to mean total flavonoid intakes estimated at >80% (). The main contributors to flavanol intakes in Western Europe are chocolate, apples, red wine and tea. Apples are widely consumed and therefore an important source of flavanols in the diet. In this study we investigated the acute and long term effects of apples (delivered as a puree) containing two different levels of flavanols (25 and 100 mg epicatechin), on platelet function, serum lipid profiles, and plasma concentrations of nitric oxide metabolites, CRP, vitamin C and endothelin-1. 

Experimental methods
Unless specifically stated all measurements were conducted at the Institute of Food Research in Norwich.

Chemicals and reagents. 
The conjugated antibodies CD61 and CD62 were purchased from Invitrogen (Paisley, UK) and Pac-1 from Becton Dickenson (Oxford, UK). ADP, epinephrine and collagen were supplied by Biodata (Alpha laboratories, Hampshire, UK). The Chemiluminescent ET-1 immunoassay kit was supplied by R&D systems (Abingdon, UK). The enzymes β-glucuronidase (Helix pomatia type H5), and sulfatase (H. pomatia type H1), were purchased from Sigma-Aldrich (Poole, UK) and β-glucuronidase, (type IX-A from E. coli) and sulfatase, (type VIII from Abalone Entrails) from Sigma (St. Louis, MO, USA). The phenolic standards (taxifolin, (-)-epicatechin, sinapic acid, galangin, (+)-catechin, phloretin) were obtained from Extrasynthese (Genay, France). All other chemicals were of analytical or HPLC grade. 

Participants and study design. 
Forty seven potential participants were assessed for eligibility on the basis of a health questionnaire and the results of clinical laboratory tests. The exclusion criteria were as follows: smoking; medical conditions such as gastrointestinal disease, history of ulcers and gastro-intestinal bleeding, diabetes, cancer, heart disease, stroke, asthma or hay fever; regular use of aspirin (at least once a week), antacids or laxatives; dietary supplements (unless prepared to cease for 1 month preceding and throughout the study); clinical results at screening judged to affect the study outcome or be indicative of a health problem. Nineteen of the forty seven potential participants were excluded from this study. Seventeen did not meet the inclusion criteria at eligibility assessment and two, even though eligible, declined to participate with no reason given. Of the twenty eight participants randomized to treatment, three were withdrawn by the researcher during the study (1 because aspirin consumption was contra-indicated, 1 developed anaemia and 1 developed an allergy) (see fig 1 for progress of participants through the phases of the crossover trial). Characteristics of the twenty five participants (13 men and 12 women) who completed the study were (mean ± SD); weight 77.5 ± 13.8 kg (range 54.8 – 108.4 kg), BMI 25.9 ± 4.2 kg/m2 (range 20.9 – 33.5 kg/m2) and age 42 ± 11 years (range 23 – 64 y). This study was conducted in the Human Nutrition Unit at the Institute of Food research, (UK) according to the guidelines laid down in the declaration of Helsinki and all procedures involving human subjects were approved by the Human Research Governance Committee of the Institute of Food Research and the Norfolk Research Ethics Committee (ref no: 06/Q0101/22). Each participant gave written informed consent prior to taking part in the trial. The trial is registered with clinicaltrials.gov (NCT00568152).
	The study was a randomized, three-phase crossover design, investigating the acute and long term effects of consuming apple puree containing different amounts of flavanols on risk markers for cardiovascular disease. An aspirin treatment was used as a positive control. Each of the three test phases comprised a 4-week period of intervention followed by a washout period of at least 2 weeks. During each period of intervention participants excluded from the diet food sources that are rich in flavanols (e.g. cocoa, berries, grapes, red wine, apples and legumes) and limited others (e.g. tea and coffee). In addition, consumption of alcohol and oily fish were also limited. However, these foods and beverages were completely excluded from the diet 48 h before blood sampling.  A list of authorized and prohibited foods was given and compliance was monitored with the use of food diary records. Participants were assessed at the start (d 1), middle (d 15) and end (d 29) of the intervention period. On d 1 of each intervention period a fasting blood sample was obtained following which participants commenced the low flavanol diet as described above. On d 15 of the intervention period fasted participants had an intravenous cannula inserted and a baseline blood sample (0 h) was obtained. Participants were given a standard breakfast consisting of 2 slices of white toast (72 g) with spread (10 g) followed by either, 230 g apple puree containing 100 mg epicatechin (HF-apple puree), 230 g apple puree containing 25 mg epicatechin (LF-apple puree) or aspirin (75mg dispersed in 100 ml water).  To limit variation in food and drink intakes, participants refrained from drinking and eating for 2 h after the treatment. Further blood samples were collected at 2, 6 and 24 h. For 24 h before and after consumption of the apple puree, participants were instructed to collect all urine passed. Daily consumption of the respective treatment was continued until d 29 of the intervention period following which another fasted blood sample and 24 h urine collection was obtained. 
	On d 1, 15 and 29 fasting blood samples were collected for assessment of plasma C-reactive protein (CRP), vitamin C, lipid profile (total cholesterol, HDL, LDL, triglycerides) and whole blood platelet reactivity. Samples for Endothelin-1 (ET-1) and NO metabolites assessment were obtained on d 15 and 29. Platelet reactivity and NO metabolites were also assessed at 2, 6 and 24 h after consumption of the treatment on d 15.  
Plasma samples from 16 individuals collected at 0, 2, 6, and 24 h on d 15 were also used to quantify epicatechin concentrations. Urine was assessed for excretion of epicatechin before treatment and after acute and long term treatment. Sub-samples of each 24 h collection were stored at -40oC until analysis (see Fig 2 for overview of sample collection time points).

Apple purée preparation and analysis. 
Two varieties of apples (Golden Delicious and Mitchalin, provided by Coressence Ltd) selected for their differences in natural levels of flavanols were harvested for this study; the cores were removed (but the skins retained) and the apples sliced and frozen. The frozen apple slices were processed by Campden and Chorleywood Food Research Association to produce food grade apple purees. This involved defrosting and gently heating the apples to cook/soften them, addition of citric acid to achieve pH ≤3.8, passage through a colloidal mill to produce puree and then a period of heating at 85°C to pasteurise the puree prior to hot filling of lacquered cans and sealing of the cans. The apple purée was packaged into individual 230 g portions. Quantification of flavanol content of the apple purees was determined at the start and then at regular intervals throughout the study, and was similar to the predicted content based on the flavanol content or raw apples. Samples of apple puree were freeze dried and ground into a powder. Freeze dried powder (40 mg in triplicate) was extracted with 70% methanol (950 µl) at 70oC for 20 min with 50 µl galangin (100 mg/L) added as an internal standard. The supernatant was filtered into auto-sampler vials and analysed by HPLC with an Agilent HP1100 using a Luna, silicon (2) column (250 x 4.60 mm, 5 micron particle size; Phenomenex). The mobile phase consisted of (A) dichloromethane, (B) methanol and (C) aqueous acetic acid (1:1 v/v). Samples were eluted with an increasing gradient of (B) as follows: 0-30 min, 14 – 28.4%, 30-45 min, 28.4 – 39.2%, 45 – 55 min, 39.2 – 86% and 55 – 65 min, 86 – 14% at a flow rate of 1ml/min. Subsequently, the eluent was passed through a fluorescence detector (excitation wavelength 276 nM, emission 316 nM). The contents of phenolics in the low and high-flavanol apple purees were as follows [all mg (g fresh weight puree)-1]: Total hydroxycinnamates-quinic acid esters, 0.138 and 0.497; Total flavanols, 1.037 and 2.020; Total dihydrochalcones. 0.055 and 0.067; Total flavonols, 0.095 and 0.066, respectively.

Vitamin C analysis. 
Whole blood collected into EDTA tubes was immediately centrifuged at 2000 g for 10 min at room temperature. Plasma samples (200 µl) were aliquoted into tubes containing 200 µl MPA to prevent degradation. Prior to analysis samples were vortex mixed and centrifuged at 13,000 g for 5 min. After centrifugation a sub-sample (100 µl) was added to ice-cold 6% MPA solution (300 µl) and centrifuged at 13,000 g for a further 5 min. Supernatant (300 µl) was added to an auto-sampler vial and analysed by HPLC (Agilent HP1100) using a Lichrosphere 100 RP-18 column (250 x 4.6 mm) with a 5 µm particle size; Merck). The mobile phase (water - pH 2.2 acidified with sulphuric acid) was pumped through the column at a flow rate of 1.0 ml/min over 10 min. Due to the labile nature of ascorbic acid all samples were prepared under gold lighting, kept on ice throughout and analysed within 4 h.   

CRP and lipid profile measurements. 
Whole blood collected into serum separating tubes was allowed to clot for 30 min before centrifugation at 2000 g for 10 min. CRP and lipid (total cholesterol/HDL/LDL/triglycerides) analysis was performed following standard protocols at the pathology department at the SPIRE hospital in Norwich. 

ET-1 and nitric oxide metabolites analysis. 
For ET-1 analysis whole blood was collected into serum separating tubes and allowed to clot for 30 min prior to centrifugation at 2000 g for 10 min. Serum samples were subsequently stored at -40oC until analysis. Samples were assayed in batches using a commercially available chemiluminescent immunoassay kit according to the manufacturer’s instructions. All samples and standards were measured in duplicate and analysed on a luminoskan ascent luminometer (Thermolab systems). Quantification of ET-1 in serum was based on standard curves (range 0.4 - 2.3 ng/L) for each of the plates used. 
	For measurement of NO metabolites in plasma, whole blood samples were collected into EDTA tubes and immediately centrifuged at 1000 g for 10 min. Plasma aliquots were snap frozen into cryovials and stored at -40oC until analysis. Analysis of nitric oxide metabolites in plasma was conducted at the RKILT-Institute of Food Safety, Wageningen. The analysis was performed as described by Feelisch et al  ADDIN EN.CITE () with only minor modifications. Briefly, a water-jacketed reaction vessel, kept at 60 ºC, was filled with 20 mL freshly prepared Browns solution. The Browns solution was stored on ice in the dark until use and made as follows: 0.65 M KI and 0.3 M I2 in milli-Q H2O (shaken for 5 min at 250 rpm) was subsequently mixed with glacial acetic acid (1: 121/3) followed by ultrasonic treatment for 5 min. Plasma samples, without any pretreatment, were injected into the reaction vessel in triplicate (50 µL) through a septum that was replaced after each series of measurements. Inside the reaction vessel NOx (NO2, NO2-, and nitrosated and nitrosylated species (RNOs/ RSNOs) were reduced to NO (g). Helium functioned as a carrier gas to transport the NO (g) through a condenser (3 ºC) followed by a 1 M NaOH solution, which was kept on ice, to remove traces of acids. Subsequently, the NO (g) passed a 0.22 µm filter before it entered a chemiluminescence detector (CLD 88 et., Eco Physics, Duernten, Switzerland). The detection range was set at 0-50 ppb. 
	The whole system was kept at a constant overpressure of 1-1.05 bar throughout the measurements. Browns solution was refreshed when peak broadening appeared or big bubbles were generated in the reaction vessel. Calibration curves were made with potassium nitrite (0-1000 nM) solved in a physiologic saline solution (0.9 % NaCl) (R2> 0.99). A standard plasma sample, which was stored in small batches at -80°C, was used to determine the reproducibility of the NO metabolite measurements. This control sample had an average NO metabolite content of 145 nM (14 measurements of duplicates). The coefficients of variation were calculated to be 6.9 % within days (14 duplicates) and 12.4 % between days (n=14). Results of a series of analysis were rejected when the value obtained in this control sample exceeded ± 2 x SD from the average level. All samples from one person were analyzed on the same day

Assessment of platelet reactivity. 
Whole blood (3.0 mL) was collected directly into sodium citrate (3.2%) after discarding the first 2.0 mL of the draw. Samples were drawn with as little pressure as possible and without the use of a tourniquet. Manipulation of the sample was kept to a minimum and samples were processed within 10 min of collection. 
	Whole blood (25 μL) was incubated for 10 min in polystyrene tubes (Sarstedt) at room temperature with Mg-Hepes buffer (PH 7.4 unstimulated control), ADP (final conc. 10 µmol/L), epinephrine (final conc. 10 µmol/L) or collagen (final conc. 4 mg/L). After 10 min samples were suspended in 1.0 mL Mg-Hepes buffer. 100 µl aliquots of each of the activated mixes was then transferred into tubes containing saturating concentrations of the fluorescent labelled monoclonal antibodies, Pac-1 - fluorescein isothiocyanate (FITC). CD61 - allophycocyanin (APC) and CD62 – phycoerythrin (PE) and incubated in the dark at room temperature for 20 min. Following antibody binding samples were fixed with 1% paraformaldehyde to prevent further in-vitro platelet activation, and stored in the dark until analysis. 
	The CD61-APC probe was used as a platelet identifier. Pac-1- FITC recognizes the integrin-β3 conformation of the fibrinogen binding receptor on activated platelets. CD62- PE recognizes P-selectin which is a component of the α-granule membrane and is expressed at the surface of the activated platelet. All buffers were filtered and brought to room temperature before use. All analyses were performed in duplicate.
	All samples were analysed on the day of collection using a Beckman Coulter Cytomics FC500 MPL flow cytometer. Instrument performance was verified using Flow Check Fluorospheres before sample acquisition. The acquisition protocol, including compensation settings, was set up prior to the start of the study using appropriate positive and negative controls. A total of 30,000 events were collected and platelets differentiated from other blood cells by their characteristic light scatter profile and by gating for CD61 positive events. Following data acquisition by flow cytometry, data analysis was performed using CXP software (Beckman Coulter V.2.1). Activated platelets were defined as the percentage of CD61 positive events that expressed CD62 or Pac-1.

Extraction & quantification of epicatechin in plasma. 
Analysis and quantification of epicatechin in plasma was conducted at the Nestle Research Centre, Switzerland. Duplicate aliquots of thawed plasma (300 µL each) were spiked with 20 µL of 15 µM internal standard (sinapic acid) solution (concentration in sample = 1 µM) and 300 µL β-glucuronidase/sulfatase enzyme solution. The enzyme solution was prepared by adding 600 units of β-glucuronidase and 60 units of sulfatase to 300 µL of 0.1 M sodium acetate (pH 5.2) per sample. Samples were incubated for 60 min at 37 ºC with 400 rpm before diluting with water (400 µL). The solid-phase extraction consisted of 4 steps: conditioning with MeOH and water, loading of the plasma samples, washing with 5% MeOH, and eluting with MeOH and ACN. Post elution, samples were dried under a stream of nitrogen, resuspended, and transferred to UPLC certified vials (Waters). The samples were analysed using a method similar to that described by Renouf et al  ADDIN EN.CITE ().

Extraction & quantification of epicatechin metabolites in urine. 
Taxifolin 10 µl (1 mg/L) was added to sub-samples of acidified urine (200 uL) as an internal standard. Samples were incubated with phosphate buffer (100 µl; pH 5.0) and enzymes (β-glucuronidase and aryl-sulfatase) for 2 h. Following incubation, samples were acidified with formic acid (5 µl), centrifuged at 17,000 g for 15 min at 4°C and the supernatant transferred into auto-sampler vials for analysis as described by Saha et al (). The quantification of total (-)-epicatechin in urine was based on matrix-matched external standard curves of (-)-epicatechin (10-1000 µg epicatechin / L urine) extracted in the same way as the samples and analysed immediately before after each batch of samples. The analytical protocol required that samples were re-extracted and re-analysed if the response factor of the post-sample standard curve was >10% different from the pre-sample standard curve, but this did not occur. Standard curves were linear with regression coefficients >99%. The limit of detection was 1.0 µg epicatechin / L urine. 

Statistical analysis. 
Data were analysed with linear models using R (R Development Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2006 Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org (​http:​/​​/​www.R-project.org​)). For all models, regression diagnostics were checked to determine if data transformations, outlier omissions or alternative non-parametric models were required. Data were analysed to assess the effects of time and treatment. Plasma polyphenol data were analysed with a T-test. Results were considered significant if P<0.05 for all tests.

RESULTS 
Data were analysed to assess the effects of acute and long term consumption of HF and LF-apple puree on platelet function and serum lipid profiles, and plasma concentrations of nitric oxide metabolites, CRP, vitamin C and endothelin-1. (See Fig 2 for details). An aspirin treatment (ASA) was used as a positive control.  

Changes in biomarkers during low flavanol diet run-in periods (d 1-14). 




Acute effects of apple puree consumption (d15 – t = 0, 2, 6 & 24 h) 
Platelet reactivity: Neither apple puree treatment attenuated collagen-induced integrin-β3 or p-selectin expression during the acute phase of ingestion (data not shown). However, HF-apple puree did significantly attenuate epinephrine-induced integrin-β3 expression 2 h after ingestion (p=0.0242) and ADP- induced integrin-β3 expression 6 h after ingestion (p=0.0005) (Fig 3A). After 24 h the latter was found to be significantly higher than at baseline (p=0.0136). LF-apple puree on the other hand significantly attenuated both ADP and epinephrine-induced integrin-β3 expression 2 h (p=<0.0001 and 0.0012 respectively) and 6 h (p=<0.0001 and 0.0426 respectively) post ingestion (Fig 3A). Furthermore, LF- apple puree attenuated both ADP and epinephrine-induced P-selectin expression 2 h after ingestion (p=0.0027 and 0.0120 respectively) (Fig 3B).  Whilst both apple puree treatments were shown to be effective at attenuating platelet reactivity 2 and 6 h after ingestion there were no significant differences in platelet reactivity between the two apple puree treatments at either of these time points. 

In this study, ASA ingestion served as a positive control and as expected significantly attenuated both ADP and epinephrine-induced integrin-β3 expression throughout the acute phase of ingestion (p=<0.05 for all time points) (Fig 3A). Collagen-induced integrin-β3 expression was only attenuated 24 h after ingestion (p=0.0015) (data not shown). Similarly, ASA ingestion only attenuated ADP-induced p-selectin expression 2 h after ingestion (p=0.0016) (Fig 3B). The acute effects of apple puree ingestion were compared with the aspirin treatment at the 2 and 6 h time points when the differences were most apparent. Compared with HF-apple puree, ASA was significantly better at attenuating ADP-induced P-selectin expression 2 h after ingestion (p=0.0119). Otherwise, no differences between apple puree and ASA were observed 2 and 6 h post consumption.  

Nitric oxide metabolites: There was a significant increase in plasma total NO metabolites conc. 6 h after consumption of HF-apple puree (170 ± 59 compared with 129 ± 37 nmol/L p=0.0297). Additionally, there was a significant increase in plasma total NO metabolites conc. 6 h after consumption of LF- apple puree (176 ± 99 compared with 116 ± 32 nmol/L p=0.0388) (see Table 1). There were no between- treatment differences in plasma NO metabolites at any time point. 

Mean 2 h plasma total monomeric catechins ((-)-epicatechin and (+)-catechin) concentrations were significantly higher after ingestion of the HF-apple puree compared with LF-apple puree (mean ± SEM: 181 ± 28 nmol/L compared with 44 ± 12 nmol/L, p=0.007), and at 6h (59 ± 10 nmol/L and nd, p=0.0001). The Tmax of epicatechin of 2 h was consistent with absorption in the small intestine. 

Long term effects of apple puree consumption (d 15-29) 
Platelet reactivity: LF-apple puree significantly attenuated collagen-induced p-selectin expression after 2 weeks daily ingestion (p=0.0018). No other decreases on platelet activity were observed. However, a significant increase in ADP-induced integrin-β3 and P-selectin expression (p=0.0105 and 0.032 respectively) was observed after 2 weeks of HF-apple puree ingestion (data not shown). As mentioned previously ASA ingestion served as a positive control. Only collagen-induced p-selectin expression was attenuated after 2 weeks daily ingestion of ASA (p= 0.0018). 

Plasma lipids, CRP, vitamin C & serum ET-1: 2 weeks daily consumption of LF-apple puree significantly decreased plasma triglycerides (1.3 ± 0.4 mmol/L (d 15) compared with 1.1 ± 0.4 mmol/L (d 29); p=0.002). When comparing the effects of the different treatments after 14-d, plasma conc. of vitamin C were significantly higher in the ASA and HF-apple puree groups compared with the LF-apple puree group (p=0.046 and 0.0087). No other significant changes in plasma CRP, vitamin C, lipids (total cholesterol, LDL and HDL-cholesterol) or serum ET-1 were observed (see Table 1). 

Urinary excretion of epicatechin metabolites. 




In this study, two hypotheses were tested: (1) consumption of flavanol-containing apple puree would attenuate platelet reactivity and increase plasma concentration of nitric oxide metabolites, (2) apple puree with a significantly higher content of flavanols would have a greater effect than apple puree with lower flavanol content. Our data show that consumption of both apple purees attenuated platelet reactivity, as measured by surface expression of two platelet activation markers (the cell adhesion molecule P-selectin and the integrin-β3) in agonist-treated whole blood samples post-consumption compared to baseline, but that the high flavanol apple puree was no more effective than the low-flavanol apple puree. Further, our data clearly show that the effects of apple puree consumption on platelet reactivity are transient, i.e. although effects were observed at 2 h and 6 h post consumption, they were not observed 24 h post-consumption nor after a 14 d period of daily consumption. The changes in platelet reactivity were observed in subjects whose flavanol intake had been restricted prior to the 2-week period of consumption of apple puree, and it is not possible to predict whether or not similar effects would be observed in subjects whose flavanol intake had not been restricted.
	Previous human and animal intervention studies using flavanol rich extracts and foods such as cocoa  ADDIN EN.CITE (,,,), and grapes  ADDIN EN.CITE (,) have also shown that flavanols improve vascular function and decrease platelet aggregation. Evidence for these anti-aggregatory effects appears to be strongest for cocoa which, consistent with our study, decreases ADP and epinephrine activated platelet aggregation within 2-6 hours post dosing  ADDIN EN.CITE (,). In these studies the effects were shown to be attributable to a decrease in the expression of P-selectin and integrin-β3. By contrast such effects are not seen after consumption of foods and beverages rich in other flavonoids such as orange and grapefruit juice  ADDIN EN.CITE (,)  and white wine ().
	Contrary to other published reports  ADDIN EN.CITE () investigating the effects of flavanol containing foods and beverages on platelet activity, we largely did not observe an effect of apple puree on platelet reactivity following 2 weeks daily consumption. In our study long term assessment of platelet function was undertaken following a 12 h overnight fast. Monomeric flavanols are absorbed rapidly with maximum plasma concentrations peaking at about 2 hours after consumption and returning to baseline levels within 24h  ADDIN EN.CITE (). Therefore, it is likely that the biological effects (in terms of platelet function) of the circulating flavanols and their phase-2 metabolites are only observed in the first few hours after consumption, and would not be observed in fasted volunteers at the end of the 2 week treatment period. Neither did we observe attenuation of collagen-induced platelet activity in response to acute or long term consumption of apple puree. It is well recognized that different platelet agonists trigger different activation pathways in response to different stimuli. For example, Murphy et al  ADDIN EN.CITE () report a significant decrease in ADP and collagen-induced platelet aggregation but not arachidonic acid-induced platelet aggregation after feeding healthy subjects cocoa flavanols and procyanidins. Conversely, Bydlowski and colleagues (), report a significant decrease in ADP and arachidonic acid-induced platelet aggregation after supplementing animals with a coffee extract but observed no effects on collagen-induced platelet aggregation. 
	It has been reported that the major metabolites arising as a result of colonic fermentation of dietary flavanols are the valerolactones, with the major reported forms being 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone and 5-(3-methoxy-4’-hydroxyphenyl)-γ-valerolactone  ADDIN EN.CITE (). These appear in plasma within about 4-6 h of consumption of flavanol-rich foods/extracts and are excreted over the next 48 h  ADDIN EN.CITE (). Although we did not quantify valerolactones in plasma or urine samples from this study, our data are consistent with hydroxyphenyl-γ-valerolactones not significantly affecting platelet reactivity at the concentrations achieved from a 25-100 mg doses in apple purees because no effects were observed in fasted samples. Further, these observations imply that the effects observed in the acute phase are likely due to flavanols such as (-)-epicatechin and (+)-catechin and their phase-2 conjugates rather than the hydroxyphenyl-γ-valerolactones.
Not all studies using flavanol containing foods and beverages show a positive effect on platelet function.  Duffy et al () for example, report no such effects after acute or chronic consumption of black tea in patients with coronary artery disease, although any small effects may have been masked by daily aspirin consumption taken as part of the subjects therapeutic regime. Regardless, similar results have been reported by Hodgson et al  ADDIN EN.CITE () after feeding healthy subjects 5 cups/day of black tea over a 4 week period. In a separate study the same authors report no effect of black tea on platelet aggregation during the acute phase of consumption  ADDIN EN.CITE (). One such explanation for the difference in these findings compared to those described earlier is that grapes, cocoa and apples contain monomeric catechins which in black tea are converted to theaflavins and thearubigins during the fermentation process () thus reducing the biological impact in terms of platelet function. 
The data presented here show that consumption of both the high and low flavanol apple purees transiently attenuates platelet reactivity and increases in plasma nitric oxide metabolites. Indeed, the magnitudes of the changes in these markers in response to the apple purees were similar. These findings prove our original hypothesis wrong. There are at least 2 plausible explanations of this finding. First, it is possible that other components in the apple puree (not the flavanols) are responsible for the effects seen in platelet reactivity and NO metabolite bioavailability. For example, other apple polyphenols such as chlorogenic acid, quercetin, and phloretin could have caused the physiological changes that were observed. It is worth noting that although the chlorogenic acid content of the high flavanol apple puree was significantly higher (3.6-fold) than the low flavanol apple puree, this was not associated with any significant changes in the biomarkers assessed in this study. Although there is increasing evidence that other non-flavanol polyphenols such as quercetin can improve vascular bioavailability of NO (9), this has only been shown for substantially higher doses than consumed in the study reported here. A second explanation is that the lower dose of apple puree flavanols (25 mg) was sufficient to induce the maximal decrease in platelet reactivity and increase in NO metabolite bioavailability, and increased doses above 25 mg do not increase the magnitude of the response. It is interesting to note that a systematic analysis of all the data from studies investigating the effects of cocoa flavanols on blood pressure with subsequent fitting of the epicatechin dose and response data to a non-linear meta-regression model (and applying a Bayesian approach using Markov chain Monte Carlo methods to appropriately deal with the non-linearity), indicated that 25 mg of epicatechin was sufficient to induce maximal responses in systolic and diastolic blood pressure  ADDIN EN.CITE (). The plasma levels of epicatechin were significantly different between the apple puree consumption groups. Phloretin, a dihydrochalcone typically found in apples, was present in plasma after apple puree consumption, but not after aspirin consumption, confirming the compliance to apple puree consumption (results not shown). Another possible explanation of our results is that non-phenolic components of apple purees are responsible for the observed effects. For example, apples contain nitrates which are a potential source of nitric oxide that can affect the endothelium  ADDIN EN.CITE (). We did not measure nitrates in the apple purees, but typical levels are around 0.3 mg/100g(). In our study, participants ingested 230 g of apple puree, thus providing the equivalent of ~ 0.69 mg nitrates. Other human intervention studies have demonstrated a positive effect of nitrate containing foods/beverages on cardiovascular health, but the effective doses delivered in these studies (≥350 mg nitrate/day) far exceed that used in our study  ADDIN EN.CITE (,).
Aspirin is the most commonly administered non-steroidal anti-inflammatory drug that significantly attenuates platelet activity as measured by surface expression of platelet receptors integrin-β3  ADDIN EN.CITE (). In our study, aspirin significantly attenuated ADP and epinephrine-stimulated integrin-β3 expression at 2, 6 and 24h post consumption. The effects of aspirin on P-Selectin expression were less profound, with attenuation occurring only 2h after consumption and only in response to ADP. Since the main effects of apple puree on platelet reactivity occurred 2 and 6h after consumption, we compared the differences in ADP and epinephrine–induced platelet reactivity between each of the treatments at these time points. P-selectin expression after ex-vivo stimulation of platelets with ADP was significantly lower in the aspirin treated group compared with the high flavanol apple puree group 2h after consumption.  Otherwise, we report no significant differences between the apple puree treatments and aspirin. This is consistent with the findings of Pearson et al  ADDIN EN.CITE () who after feeding healthy subjects a flavanol rich cocoa beverage, report a decrease in ADP and epinephrine activated platelet aggregation similar to that achievable with a low dose of aspirin (81 mg). 
In addition to inhibiting platelet activity, flavanols have been reported to affect vascular function through other mechanisms. The endothelium plays an integral role in maintaining vascular homeostasis which is partly achieved by balancing the production of vasodilators such as endogenous nitric oxide with vasoconstrictors such as endothelin-1. Previous studies have reported both acute and chronic increases in endothelium-dependant vasodilation after consumption of flavanol rich foods and beverages, as measured by flow mediated dilation (FMD) of the brachial artery  ADDIN EN.CITE (). FMD is almost exclusively mediated by NO  ADDIN EN.CITE () and flavanol containing foods and beverages have been shown to increase NO production  ADDIN EN.CITE (,).  Nitric oxide inhibits the production of endothelin-1. In our study plasma NO metabolite levels were significantly higher 6 h after subjects consumed apple puree both low and high in epicatechin, but the effect was short-lived and no change in serum concentrations of ET-1 were seen. Plasma cholesterol and C-reactive protein are predictive biomarkers of cardiovascular disease risk. Flavanol rich foods and beverages have been reported to lower plasma total and LDL-cholesterol  ADDIN EN.CITE () but contrary to these findings our study did not show an effect on plasma lipids after acute or long term intake of apple puree consumption. Consistent with other studies  ADDIN EN.CITE (,) we also report no effects of a flavanol rich food on plasma CRP concentrations.
In conclusion, our data show that consumption of apple puree containing two different amounts of flavanols transiently attenuated ex vivo integrin-β3 and P-selectin expression in healthy subjects. Further, we provide evidence that apple puree containing higher levels of flavanols are no more effective at attenuating platelet reactivity than apple puree containing low levels of flavanols. These data indicate that consumption of apples may have the potential to reduce cardiovascular disease risk by reducing agonist-induced platelet aggregation.
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Fig 1 Flow diagram of the progress of subjects through 3 phases of a randomized crossover design study.

Fig 2. Time points for blood and urinary assessment on a randomized 3-phase crossover design study. During each period of intervention assessments were made before and after 2 week low flavanol diet (days 1-15), and after acute (day 15 – t= 0, 2, 6 & 24h) and long term (day 15-29) consumption of apple puree high and low in epicatechin (100 and 25 mg respectively) and aspirin (75mg). There were no assessments made on ET-1 or NO metabolite levels during the aspirin phase.

Fig 3. Acute effects of aspirin (     ), high flavanol apple puree (     ) and low flavanol apple puree 



































































Table 1. Plasma concentrations of CVD risk markers before and after consumption of 230 g apple puree high and low in epicatechin (100 and 25 mg respectively)                           and aspirin (75mg).

Biomarker	   D1	         D15		      D29
	Mean      SD	        0h                        2h                   6hMean     SD          Mean   SD      Mean    SD      	        24h  Mean    SD  	Mean       SD  
				
 High flavanol apple puree                                   	                     			
CRP (mg/L)	3.38       2.58	  3.75       3.69                                    	          	 3.86          3.44
Vitamin C (μmol/L)	67.5       41.5	  61.7       19.1                                      	          	  84.2A        76.0
Total cholesterol (mmol/L)	5.35       0.77	  5.14       0.89                                      	          	 5.07          0.81
HDL Cholesterol (mmol/L)	1.37       0.34	  1.36       0.33                 	          	 1.30          0.31
LDL Cholesterol (mmol/L)	3.44       0.73	  3.29       0.80                 	          	 3.28          0.66
Triglycerides (mmol/L)	1.24       0.45	  1.19       0.47                                                        	          	 1.19          0.49
ET-1 (ng/L)		  0.67       0.48                 	          	 0.71          0.56
NO metabolites (nmol/L)		    129a        37           173     90         170b    59         	   147      71	 150           102
				
Low flavanol apple puree		    		
CRP (mg/L)	 3.75      3.38	    3.07       2.73                		  2.89         2.70
Vitamin C (μmol/L)	 59.1      23.9	  60.8       18.2                  		    63.0 AB     36.3
Total cholesterol (mmol/L)	 5.11      0.91	  5.16       0.89                		  5.06         0.80
HDL Cholesterol (mmol/L)	 1.39      0.32	  1.35       0.32                		  1.54         0.87
LDL Cholesterol (mmol/L)	 3.10      0.89	  3.24       0.79                		  3.09         0.79
Triglycerides (mmol/L)	 1.16      0.46	  1.25a      0.44                		  1.10b        0.44
ET-1 (ng/L)		  0.71       0.51                		  0.71         0.47
NO  metabolites (nmol/L)		  116a         32           129     49         176b    98	      150      79	  127           69
Aspirin				
CRP (mg/L)	 4.05      5.31     	    2.80       1.87                		  3.49         2.48
Vitamin C (μmol/L )	61.9       25.3	  73.2       49.0                		    66.4 B       20.7
Total cholesterol (mmol/L)	 5.32      0.99	  5.22       0.92                		  5.09         0.86
HDL Cholesterol (mmol/L)	 1.42      0.37	  1.34       0.29                		  1.32         0.28
LDL Cholesterol (mmol/L)	 3.34      0.85	  3.31       0.81                		  3.19         0.81






























                   

Values are mean ± SD. n=25. Data were analysed by 1-way ANOVA. 
ABWithin a column means with unlike upper case superscript letters were significantly different (p<0.05)
AbWithin a row means with unlike lower case superscript letters were significantly different (p<0.05)  	









n=17 did not meet inclusion criteria

n=2 declined to participate post enrolment

   












Did not complete (n=3) 









Did not complete (n=2) 









Did not complete (n=3) 







Lost to follow-up (n=3)

1 developed anaemia 
1 developed an allergy 




  Excluded from analysis (n=3)

   1 withdrawn after only completing day 1 of first allocated intervention (therefore no data available)











^1	  Abbreviations : ASA, aspirin; CRP, C-reactive protein; ET-1, endothelin-1; HF-apple puree, high flavanol apple puree; LF-apple puree, low flavanol apple puree; FMD, flow mediated dilation; TXA2, thromboxane A2; MPA, meta-phosphoric acid.
